Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Kristeleit

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
IGN-311. IgeneonHartmut Kristeleit
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Systemic treatment of non-small-cell lung cancerRohit Lal, Deborah Enting, Hartmut Kristeleit
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Basic science of lung cancerHartmut Kristeleit, Deborah Enting, Rohit Lai
European Journal of Cancer Care|November 6, 2022
Eribulin for the treatment of advanced breast cancer: A prospective observational registry studyLaura Kenny, Mark Beresford, Ian Brown, et al.
Targeted Oncology|May 17, 2016
Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast CancerHartmut Kristeleit, Marina Parton, Mark Beresford, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2018
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [<sup>18</sup>F] fluorodeoxyglucose and [<sup>18</sup>F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imagingGurdip K Azad, Benjamin P Taylor, Adrian Green, et al.
Oncology|August 31, 2022
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective StudyMariam Jafri, Hartmut Kristeleit, Vivek Misra, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
Breast Cancer Research and Treatment|January 19, 2019
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experienceNicolò Matteo Luca Battisti, Belinda Kingston, Judy King, et al.
Cancer|February 2, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trialPeter Vink, Ignacio Delgado Mingorance, Constanza Maximiano Alonso, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
IGN-311. IgeneonHartmut Kristeleit
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Systemic treatment of non-small-cell lung cancerRohit Lal, Deborah Enting, Hartmut Kristeleit
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Basic science of lung cancerHartmut Kristeleit, Deborah Enting, Rohit Lai
European Journal of Cancer Care|November 6, 2022
Eribulin for the treatment of advanced breast cancer: A prospective observational registry studyLaura Kenny, Mark Beresford, Ian Brown, et al.
Targeted Oncology|May 17, 2016
Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast CancerHartmut Kristeleit, Marina Parton, Mark Beresford, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2018
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [<sup>18</sup>F] fluorodeoxyglucose and [<sup>18</sup>F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imagingGurdip K Azad, Benjamin P Taylor, Adrian Green, et al.
Oncology|August 31, 2022
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective StudyMariam Jafri, Hartmut Kristeleit, Vivek Misra, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
Breast Cancer Research and Treatment|January 19, 2019
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experienceNicolò Matteo Luca Battisti, Belinda Kingston, Judy King, et al.
Cancer|February 2, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trialPeter Vink, Ignacio Delgado Mingorance, Constanza Maximiano Alonso, et al.
Pageof 2